Starbucks union plans Red Cup Day strike in 25+ cities - Bloomberg
Investing.com -- Bruker Corporation (NASDAQ:BRKR) reported better-than-expected third-quarter 2025 results but saw its shares fall 3.2% premarket after issuing full-year guidance below analyst expectations.
The scientific instruments maker posted adjusted earnings of $0.45 per share for the third quarter, surpassing the analyst estimate of $0.33. Revenue came in at $860.5 million, exceeding the consensus estimate of $847 million but down 0.5% YoY and 4.5% organically compared to the same period last year.
Bruker’s stock declined as the company lowered its full-year 2025 guidance, now expecting adjusted EPS of $1.85 to $1.90, below the analyst consensus of $1.94. The company projects annual revenue between $3.41 billion and $3.44 billion, at the low end of the $3.44 billion consensus estimate.
"In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bill ratio greater than 1.0," said Frank H. Laukien, Bruker’s President and CEO. "For the first time this year, we saw strength in bookings in the academic/government market segment, as well as improving biopharma and applied markets orders."
The company reported a GAAP operating loss of $51.8 million for the quarter, compared to operating income of $68.1 million in the same period last year. Results were impacted by non-cash impairment charges related to goodwill and intangible assets totaling $119.4 million and restructuring charges of $34.5 million.
Despite current challenges, Bruker noted that its cost-saving initiatives are progressing well toward the high end of its $100 to $120 million targets and are expected to deliver significant operating margin expansion and EPS growth in 2026.